ADAM12与CA125、CA15-3、CA19-9联合检测在乳腺癌诊断中的价值  

Value of combined detection of ADAM12,CA125,CA15-3,and CA19-9 in the diagnosis of breast cancer

作　　者：吴帆 Wu Fan(Department of Pathology,Jinxiang People′s Hospital,Jining Shandong,272000,China)

机构地区：[1]金乡县人民医院病理科,山东济宁272000

出　　处：《中外女性健康研究》2025年第2期29-32,共4页Women's Health Research

摘　　要：目的:探讨整合素-金属蛋白酶12(ADAM12)与糖类抗原125(CA125)、糖类抗原15-3(CA15-3)、糖类抗原19-9(CA19-9)联合检测在乳腺癌诊断中的应用价值。方法:选取本院2022年6月至2024年6月收治的110例乳腺癌患者为研究组,将同期100例乳腺良性疾病者设为良性组、108例健康体检者设为健康组。检测三组血清ADAM12、CA125、CA15-3、CA19-9值。采用Spearman分析四项血清与乳腺癌发生的相关性;ROC分析四项血清诊断乳腺癌的效能并行多因素Logistic回归分析其发生的影响因素。结果:研究组的ADAM12、CA125、CA15-3、CA19-9均高于良性组、健康组(P<0.05);良性组的上述4项指标高于健康组(P<0.05);Spearman分析显示,乳腺癌患者血清ADAM12和CA125、CA15-3、CA19-9呈正相关(P<0.05),CA125水平与CA15-3、CA19-9呈正相关(P<0.05),CA15-3水平与CA19-9呈正相关(P<0.05);ROC曲线结果显示,四项血清联合诊断乳腺癌效能高于单独诊断效能,且四项血清高表达为乳腺癌发生的危险因素(P<0.05)。结论:血清ADAM12、CA125、CA15-3、CA19-9水平在乳腺癌中可呈高表达,与乳腺癌密切相关且为其发生的危险因素,且4项指标联合诊断乳腺癌可提高诊断效能。Objective:To investigate the application value of combined detection of a disintegrin and metalloproteinase 12(ADAM12),carbohydrate antigen 125(CA125),carbohydrate antigen 15-3(CA15-3),and carbohydrate antigen 19-9(CA19-9)in the diagnosis of breast cancer.Methods:A total of 110 patients with breast cancer admitted to our hospital from June 2022 to June 2024 were selected as the study group.Additionally,100 patients with benign breast diseases during the same period were included as the benign group,and 108 healthy individuals undergoing physical examination were included as the healthy group.The serum levels of ADAM12,CA125,CA15-3,and CA19-9 were measured in all three groups.Spearman’s correlation analysis was used to assess the correlation between the four serum markers and the occurrence of breast cancer.Receiver operating characteristic(ROC)curve analysis was performed to evaluate the diagnostic efficiency of the four serum markers in breast cancer,and multivariate logistic regression analysis was conducted to identify the influencing factors.Results:The study group showed higher levels of ADAM12,CA125,CA15-3,and CA19-9 compared to the benign group and healthy group(P<0.05).The benign group also had higher levels of these four markers compared to the healthy group(P<0.05).Spearman’s correlation analysis revealed positive correlations between serum ADAM12 and CA125,CA15-3,CA19-9 in breast cancer patients(P<0.05),between CA125 and CA15-3,CA19-9(P<0.05),and between CA15-3 and CA19-9(P<0.05).ROC curve analysis showed that the combined detection of the four serum markers had higher diagnostic efficiency for breast cancer than any single marker alone.High expression of all four serum markers was identified as a risk factor for breast cancer(P<0.05).Conclusion:Serum levels of ADAM12,CA125,CA15-3,and CA19-9 are highly expressed in breast cancer and are closely related to its occurrence,serving as risk factors.Combined detection of these four markers can improve the diagnostic efficiency for breast cancer.

关 键 词：乳腺癌 整合素-金属蛋白 糖类抗原 肿瘤标志物 诊断效能 

分 类 号：R737.9[医药卫生—肿瘤]